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ABSTRACT
MYCN is a transcription factor that plays key roles in both normal development 
and cancer. In neuroblastoma, MYCN acts as a major oncogenic driver through 
pleiotropic effects controlled by multiple protein encoding genes as well as microRNAs 
(miRNAs). MYCN activity is tightly regulated at the level of transcription and protein 
stability through various mechanisms. Like most genes, MYCN is further controlled 
by miRNAs, but the full complement of all miRNAs implicated in this process has not 
been determined through an unbiased approach. To elucidate the role of miRNAs 
in regulation of MYCN, we thus explored the MYCN-miRNA interactome to establish 
miRNAs controlling MYCN expression levels. We combined results from an unbiased 
and genome-wide high-throughput miRNA target reporter screen with miRNA and 
mRNA expression data from patients and a murine neuroblastoma progression model. 
We identified 29 miRNAs targeting MYCN, of which 12 miRNAs are inversely correlated 
with MYCN expression or activity in neuroblastoma tumor tissue. The majority of 
MYCN-targeting miRNAs in neuroblastoma showed a decrease in expression during 
murine MYCN-driven neuroblastoma tumor development. Therefore, we provide 
evidence that MYCN-targeting miRNAs are preferentially downregulated in MYCN-
driven neuroblastoma, suggesting that MYCN negatively controls the expression of 
these miRNAs, to safeguard its expression.
INTRODUCTION
MYCN acts as a major driver oncogene in 
neuroblastoma, a pediatric tumor of the sympathetic 
nervous system. Genomic amplification of this gene occurs 
in about half of all high-stage neuroblastoma tumors and 
has been associated with poor survival. As such, MYCN 
amplification has been used as one of the first biomarkers 
for therapeutic decision-making. 
MYC proto-oncogenes (MYC, MYCN, MYCL) are 
transcription factors that play key roles in both normal 
development and cancer. The MYC proteins act as direct 
amplifiers of transcriptionally active genes through 
sequence-specific binding to consensus E-box DNA 
binding sites [1-3]. In addition, MYC proteins can also 
silence genes, by a mechanism that is uncoupled from 
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E-box binding and dependent upon initiator elements in 
the basal promoter region [1,4]. Apart from the broad 
impact on transcriptional regulation of protein coding 
genes, MYCN has also been shown to tightly control the 
expression of many microRNAs (miRNAs) [1,5].
Numerous signal transduction pathways and 
regulatory mechanisms keep the expression of MYC 
family members under tight control. This regulation 
occurs at multiple levels, including gene transcription, 
messenger RNA (mRNA) turnover, and protein activity 
and stability [1-3]. miRNAs have also been shown to 
contribute to the regulation of MYC expression [2,3]. 
miRNAs are involved in the regulation of virtually all 
signaling circuits within a cell, and their dysregulation has 
been shown to play an essential role in the development 
and progression of cancer [6,7]. This class of small non-
coding RNA molecules typically inhibits the translation 
and stability of mRNA molecules and thus eventually 
controls protein levels.
In previous studies, individual miRNAs targeting 
MYCN have been identified, using miRNA target reporter 
assays to confirm predicted miRNA target sites in the 
3’ untranslated region (3’UTR) of MYCN [3,8]. Eleven 
MYCN-targeting miRNAs have thus been identified, 
of which miR-34a, miR-101, let-7e and miR-202 were 
shown to affect neuroblastoma proliferation in vitro [3,8]. 
Although the applied approach is valuable, it is biased 
towards canonical miRNA-mRNA interactions, identified 
by available prediction algorithms. 
Here, we performed a comprehensive, genome-
wide exploration of the miRNA-MYCN interactome in 
neuroblastoma. We combined results from an unbiased 
and genome-wide high-throughput miRNA target 
reporter screen with miRNA and mRNA expression 
data from patients and identified 12 MYCN-targeting 
miRNAs in neuroblastoma tumor tissue. Subsequently, 
the dynamic regulation of MYCN-targeting miRNAs 
during neuroblastoma development was evaluated in a 
murine neuroblastoma progression model. We provide 
evidence that MYCN targeting miRNAs are preferentially 
downregulated in MYCN-driven neuroblastoma tumors, 
suggesting that MYCN negatively controls the expression 
of these miRNAs, and as such safeguards its own 
expression. Hence, our findings further clarify the role of 
miRNAs in the regulation of MYCN in neuroblastoma 
and describe a negative feedback loop from MYCN to its 
targeting miRNAs.
RESULTS
An unbiased MYCN 3’UTR-miRNA library 
screen identifies 29 miRNAs targeting MYCN 
Potential interactions of 470 miRNAs with the 
3’UTR of MYCN were assayed in a high-throughput 
luciferase reporter screen. In brief, human embryonic 
kidney cells (HEK293T) were co-transfected with 
a reporter construct, containing the MYCN 3’UTR 
downstream of a luciferase reporter gene, and each 
of the individual miRNA mimics from a 470 miRNA 
mimic library. Based on the relative luciferase activities 
in two independent screens (Supplementary Fig. S1), an 
interaction score was calculated for each miRNA-MYCN 
combination (see Material and Methods). This effort 
was part of a large-scale 3’UTR screening in which the 
interactions of 470 miRNAs with 17 selected cancer- and 
Figure 1: An unbiased MYCN 3’UTR-miRNA library screen identifies 29 miRNAs potentially targeting MYCN. (A) 
Average interaction scores are plotted (Y-axis) for 470 tested miRNAs (X-axis). The 29 miRNAs with an interactions core of < -1.94 are 
listed in Fig. 2A. The 11 interactions that have been reported in literature, are indicated in black. (B) Cumulative distributions (Y-axis) of 
the interaction scores (X-axis) of miRNAs that respectively have 6-, 7- or 8-mer seed-matches in the MYCN 3’UTR. 
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disease-associated genes were probed (Van Peer et al., in 
preparation).
Applying this strategy, we identified 29 miRNAs 
with a high probability of targeting MYCN (interaction 
score < -1.94; see Material and Methods; Fig. 1A, Fig. 
2A and Supplementary Table S6). All 11 previously 
established miRNA-MYCN interactions [3,8] were 
validated in our screen (Fig. 1A). In the same studies, 9 
miRNAs predicted to target MYCN could not be validated; 
this is now confirmed by our data. Additionally, 18 new 
MYCN targeting miRNAs were identified, of which 
only 2 are predicted to target MYCN by MirTarget2, 
underscoring the value of this screening method to detect 
novel, predicted as well as non-predicted, miRNA-target 
Figure 2: Integration of 3’UTR-miRNA library screen and patient expression data identifies 12 MYCN-targeting 
miRNAs in neuroblastoma. (A) MYCN targeting miRNAs are filtered for their relevance in neuroblastoma according to two criteria: 
significant negative correlation to MYCN expression in a MYCN non-amplified neuroblastoma patient cohort and negative enrichment for 
MYC(N) gene sets, using Gene Set Enrichment Analysis. 12/29 miRNAs match with at least one of these criteria and are considered to be 
relevant for neuroblastoma. n.s.: not significant (Spearman correlation, Benjamini & Hochberg multiple testing corrected p-value > 0.05); 
n.d.: no data available. (B) The cumulative distribution (Y-axis) of the π-value for the correlation between miRNA and MYCN expression 
(X-axis) of miRNAs that were identified as either MYCN-targeting (black) or not MYCN-targeting (gray). Kolmogorov-Smirnov test, 
p-value = 1.4 x 10-3. (C) 2x2 contingency table for negative enrichment of MYC(N) gene sets of MYCN-targeting and other miRNAs. 
Chi-Square test.
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gene interactions. The top 5 miRNAs (miR-449b-5p, 
miR-767-5p, miR-98-5p, let-7b-5p and let-7f-5p) not 
reported in literature were validated by demonstrating 
rescue of reporter gene downregulation upon mutation of 
potential binding sites (Van Peer et al., in preparation). 
Among the strongest hits in the screen, a significant 
enrichment was observed for both miRNAs with seed-
matched sites present in the MYCN 3‘UTR (Fig. 1B) and 
MirTarget2 (Supplementary Fig. S2) predicted miRNAs, 
thus further underscoring the sensitivity and robustness of 
the screen. 
Integration of 3’UTR-miRNA library screen and 
patient expression data identifies 12 MYCN-
targeting miRNAs in neuroblastoma
miRNAs are known to regulate their target genes 
in a highly tissue- and cell type specific manner [9]. As 
the MYCN 3’UTR-miRNA library screen was performed 
in HEK293T cells, we next aimed to specifically select 
miRNAs targeting MYCN in neuroblastoma cells by 
integrating the obtained screen results with miRNA 
expression data from primary neuroblastoma tumors. 
We reasoned that the expression of a targeting miRNA is 
inversely correlated to MYCN mRNA expression levels or 
MYCN activity in primary tumor samples. Assuming that 
miRNAs would have more impact on MYCN expression 
levels and activities in MYCN non-amplified cells, we 
chose to assess miRNA correlations with MYCN mRNA 
levels and activity only in this tumor subset to infer a 
potential regulatory relationship. 
Correlation to MYCN mRNA expression
Overall, MYCN targeting miRNAs showed stronger 
inverse correlation to MYCN mRNA levels compared to 
non-targeting miRNAs (Fig. 2B), as indicated by a shift of 
the cumulative distribution of π-values (-log10 p-value * 
Pearson correlation coefficient) to more negative values. 
Of the 25 MYCN-targeting miRNAs that were included 
on the human miRNA expression platform, 8 miRNAs 
showed statistically significant inverse correlation to 
MYCN mRNA expression, suggesting that they can indeed 
downregulate MYCN expression in primary MYCN 
non-amplified tumors. Three miRNAs were positively 
correlated to MYCN expression. Two of these miRNAs, 
miR-19a-3p and miR-19b-3p, are part of the oncogenic 
miR-17-92 cluster and were already known to be directly 
induced by MYCN in neuroblastoma cells [10].
Correlation to MYCN activity
miRNAs are known to regulate their targets 
by inducing mRNA destabilization and translational 
Figure 3: Overview of results from different analyses. Numbers listed represent the number of miRNAs. (A) Of 470 screened 
miRNAs, 29 miRNAs interact with the 3’UTR of MYCN. (B) Of these 29 miRNAs, 25 miRNAs could subsequently be analyzed in 
primary neuroblastoma tumors: 12 miRNAs are inversely correlated to MYCN expression or activity, whereas 5 miRNAs are positively 
correlated to MYCN expression or activity. (C) Of the 12 miRNAs inversely correlated to MYCN expression or activity, 10 miRNAs 
are downregulated during MYCN-driven tumor development in the TH-MYCN mouse model, 9 miRNAs are lower expressed in LSL-
MYCN;Dbh-iCre tumors compared to wild-type adrenals, and 2 miRNAs are repressed upon induction of MYCN in the SHEP-MYCN-ER 
model system. On the other hand, of the 5 miRNA correlated to MYCN expression or activity, 3 miRNAs are upregulated during MYCN-
driven tumor development in the TH-MYCN mouse model, these miRNAs are also higher expressed in LSL-MYCN;Dbh-iCre tumors 
compared to wild-type adrenals, and 3 miRNAs are induced upon induction of MYCN in the SHEP-MYCN-ER model system.
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inhibition. Assessing the correlation between miRNA 
and MYCN mRNA levels, however, will not identify 
potential regulatory effects at protein level. Therefore, 
we additionally evaluated which miRNAs are inversely 
correlated to MYCN activity as a surrogate for MYCN 
protein levels. MYCN activity is reflected in the 
expression of MYCN regulated genes and can be assessed 
using Gene Set Enrichment Analysis (GSEA) [11]. In 
brief, for each miRNA, mRNAs were ranked according 
to decreasing expression correlation in MYCN non-
amplified neuroblastoma tumors. Subsequently, GSEA 
was performed using six selected gene sets of MYC(N) 
upregulated genes [12-17] (see Materials and Methods). A 
miRNA negatively correlated to MYCN protein levels – 
and thus activity – is expected to be negatively correlated 
to genes that are positively regulated by MYCN. In this 
case an enrichment of MYCN upregulated genes can be 
expected among the most negatively correlated genes 
at the bottom of the ranked list. Here, a miRNA was 
considered to be negatively correlated to MYCN activity 
in case such negative enrichment could be observed for 
at least one MYC(N) gene set (normalized enrichment 
score < -2 and false discovery rate < 0.25). As expected, 
the MYCN-targeting miRNAs identified in the 3’UTR-
miRNA library screen were significantly enriched for 
miRNAs that showed negative enrichment for at least one 
MYC(N) gene set and thus for miRNAs that are negatively 
correlated to MYCN activity (Fig. 2C). Of the 25 MYCN-
targeting miRNAs that were included on the human 
miRNA expression platform, 11 miRNAs showed this 
inverse relation to MYCN activity, whereas 6 miRNAs 
showed a positive relation to MYCN activity (Fig. 2A, 
Supplementary Table S7).
In summary, 12 of 29 MYCN-targeting miRNAs 
were inversely correlated to either MYCN expression or 
MYCN activity in MYCN non-amplified tumor samples, 
and therefore likely regulate MYCN in neuroblastoma (Fig 
2A, Fig. 3). Interestingly, 5 MYCN-targeting miRNAs 
were positively correlated to MYCN expression or activity 
(Fig. 2A), suggesting that MYCN induces their expression 
in neuroblastoma. One miRNA, miR-34b-5p, shows both 
negative correlation to MYCN mRNA levels and positive 
correlation to MYCN activity (Fig. 2A) and is therefore 
excluded from further analyses.
miRNAs that regulate MYCN are downregulated 
during murine MYCN-driven neuroblastoma 
tumor formation.
In a next step, we explored how expression 
levels of miRNAs that target MYCN are dynamically 
regulated during MYCN-driven tumor formation. To 
this end, we performed miRNA expression profiling of 
the TH-MYCN mouse model, a murine MYCN-driven 
neuroblastoma progression model [18]. In brief, we 
sacrificed TH-MYCN+/+ mice one and two weeks after 
birth to harvest superior cervical and celiac ganglia 
containing foci of neuroblast hyperplasia, and 6-week old 
TH-MYCN+/+ mice to dissect advanced neuroblastoma 
tumors, arising from the neuroblast hyperplasia [19]. 
Additionally, we dissected the superior cervical and celiac 
ganglia from TH-MYCN-/- mice one, two and six weeks 
after birth to control for miRNA expression changes 
during normal postnatal development of the sympathetic 
ganglia. In the following analyses we only considered 
those murine miRNA assays that target sequences 
similar to the sequences of the human miRNAs included 
in our 3’UTR-miRNA library screen (n = 187, see 
Supplementary Table S6). To validate this MYCN-driven 
neuroblastoma progression model, we evaluated the 
expression of 50 known MYC(N)-regulated miRNAs [5], 
summarized in a MYCN signature score. This MYCN 
signature score increases significantly throughout tumor 
progression from tumor-prone ganglia to tumors in 
transgenic mice, compared to wild-type ganglia (Fig. 
4A and Supplementary Fig. S3). This observation is in 
keeping with the hypothesis that sustained MYCN activity 
in the sympathetic ganglia of homozygous transgenic mice 
gives rise to the appearance of neuroblastoma tumors in 
these anatomic locations [19].
The majority of the MYCN-targeting miRNAs 
in neuroblastoma (10 out of 12) showed a significantly 
decreased expression during tumor development in 
TH-MYCN+/+ mice compared to normal development, 
while 2 of them showed no significantly different 
expression pattern (Fig. 3, Fig. 4B). Interestingly, of the 
5 MYCN-targeting miRNAs with positive correlation 
to MYCN expression or activity, 3 miRNAs, miR-19a-
3p, miR-19b-3p and miR-494-3p, showed significantly 
increased expression during tumor development (Fig. 
4B), further supporting the hypothesis that MYCN 
induces the expression of these miRNAs. The 2 remaining 
positively correlated miRNAs, miR-34c-5p and miR-449a, 
are, respectively, significantly downregulated and not 
regulated during tumor development (Fig. 4B). Overall, 
the 12 MYCN-targeting miRNAs in neuroblastoma, show 
significantly more downregulation during MYCN-driven 
tumor development, compared to non-targeting miRNAs, 
as indicated by a shift of the cumulative distribution of 
the π-values (-log10 p-value *∆ slope) to more negative 
values (Fig. 4C).
The above findings could be confirmed in 
an additional, recently developed, MYCN-driven 
neuroblastoma mouse model, the LSL-MYCN;Dbh-iCre 
mouse model [20]. All 9 MYCN-targeting miRNAs that 
could be evaluated are significantly lower expressed in 
LSL-MYCN;Dbh-iCre tumors compared to wild-type 
adrenals (Fig. 3, Fig. 4D). Considering the 5 MYCN-
induced miRNAs, the data in the LSL-MYCN;Dbh-iCre 
tumors again fully recapitulated the findings from the 
TH-MYCN progression model: miR-19a-3p, miR-19b-3p 
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and miR-494-3p showed increased expression in tumors 
compared to wild-type control tissue (Fig. 4D), whereas 
miR-34c-5p and miR-449a are respectively significantly 
downregulated and not regulated in LSL-MYCN;Dbh-iCre 
tumors.
MYCN can directly modulate the expression 
levels of particular miRNAs that target its 3’UTR.
In a final step, we explored to what extent MYCN 
directly controls, as transcriptional activator and repressor, 
the expression levels of the 12 selected MYCN-targeting 
Figure 4: miRNAs that regulate MYCN are downregulated during murine MYCN-driven neuroblastoma tumor 
formation. (A) The MYCN miRNA signature score, representing expression of known MYC(N)-regulated miRNAs, increases during 
neuroblastoma progression in ganglia from TH-MYCN mice (TG, black) compared to ganglia from wild-type mice (WT, gray dashed). 
Data are presented as mean ± standard deviation of four samples. (B) Heatmap of average miRNA expression levels during murine MYCN-
driven neuroblastoma development. Data are presented as row normalized. TG: transgenic; WT: wild-type; ∆ slope: the difference in 
regression slope between TG and WT samples; n.s.: non-significant difference (Benjamini & Hochberg multiple testing corrected p-value 
> 0.05). (C) The 12 MYCN-targeting miRNAs in neuroblastoma show significantly more downregulation during MYCN-driven tumor 
development, compared to non-targeting miRNAs. Kolmogorov-Smirnov test, p-value = 9.2 x 10-3. (D) Heatmap of miRNA expression 
levels in 11 LSL-MYCN;Dbh-iCre tumors and 5 normal adrenals. For miR-29c-3p and -34a-5p, no expression data was available; miR-98-
5p was not expressed in LSL-MYCN;Dbh-iCre tumors. Data are presented as row normalized. gray: no data available. FC: log2 fold change; 
n.d.: no data available; n.s.: non-significant fold change (Student T-test, Benjamini & Hochberg multiple testing corrected p-value > 0.05).
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miRNAs. To this end we measured miRNA expression 
levels in a MYCN-inducible model system. Two out of 
12 MYCN-targeting miRNAs in neuroblastoma (Fig. 
2A), miR-29a-3p and miR-29b-3p, showed significant 
reduction in expression 48h after MYCN activation (Fig. 
3, Fig. 5). 
Of the five MYCN-targeting miRNAs with positive 
correlation to MYCN expression or activity (Fig. 2A), 
three miRNAs, miR-19b-3p, miR-19a-3p and miR-34c-5p, 
showed induction of expression (Fig. 5), supporting the 
assumption that MYCN induces the expression of these 
miRNAs.
DISCUSSION
Previous studies have highlighted the importance 
of miRNAs in the regulation of MYCN, a major 
driver oncogene in neuroblastoma. Nonetheless, a 
comprehensive, genome-wide exploration of the miRNA-
MYCN interactome has not yet been performed. Thus 
far, studies have only focused on individual miRNAs or 
a small subset of miRNAs predicted to target MYCN by 
algorithms that are biased towards the limited knowledge 
of miRNA binding site architecture. Here, we report on the 
first unbiased and genome-wide high-throughput miRNA 
target reporter screen to identify miRNAs targeting 
MYCN. From the total of 29 MYCN-targeting miRNAs 
identified in this study, 18 interactions were novel whereas 
all 11 previously established MYCN-targeting miRNAs 
[3,8] were confirmed, thus underscoring the validity of our 
genome-wide high-throughput screen.
Previously identified MYCN-targeting miRNAs 
have not been confirmed to regulate MYCN in primary 
neuroblastoma tumor cells. To address this shortcoming, 
we integrated our screen results with matching miRNA and 
mRNA expression profiles from primary neuroblastoma 
tumors. For 12 MYCN-targeting miRNAs we observed 
significant inverse correlation to MYCN expression 
or activity and thus provide evidence that they regulate 
MYCN in a neuroblastoma tissue context: eight let-7 
family miRNAs (let-7a-5p, let-7b-5p, let-7c-5p, let-7d-5p, 
let-7f-5p, let-7g-5p, let-7i-5p and miR-98), three miR-29 
family miRNAs (miR-29a-3p, miR-29b-3p, miR-29c-3p) 
and miR-34a-5p.
In a next step, we investigated the dynamic 
regulation of these miRNAs during the process of 
MYCN-driven tumor formation, using the extensively 
validated TH-MYCN mouse model. Notably, we 
observe that MYCN-targeting miRNAs are preferentially 
downregulated during MYCN-driven tumor development, 
suggesting that MYCN negatively regulates the miRNAs 
by which it is targeted, to safeguard its own expression. 
Growing evidence suggests that MYCN predominantly 
acts repressively on the overall miRNA composition 
[5,21-24] and we indeed observed widespread 
downregulation of miRNA expression during murine 
MYCN-driven neuroblastoma development (Fig. 4C, 
gray line). Nonetheless, the fraction of MYCN-targeting 
miRNAs that is downregulated is larger than expected 
by chance (Fig. 4C, black line). The mechanisms by 
which MYCN directly represses transcription are not 
fully understood. Several lines of evidence suggest that 
it acts in a protein complex including SP1 and/or MIZ-
1 [25-29] to recruit histone writers [25,27-30] and/or 
DNA-methyltransferases [26,30] to the promoter regions 
of its repressed target genes. Whether binding of MYCN 
to the canonical E-box sequence is required for this 
process is still unclear [26,31]. Notably, only two MYCN-
targeting miRNAs in neuroblastoma (miR-29a-3p and 
miR-29c-3p) are directly downregulated upon induction 
of MYCN in a neuroblastoma cell line model, suggesting 
that downregulation of MYCN-targeting miRNAs during 
Figure 5: Induction of MYCN activity is associated with altered expression levels of particular miRNAs that target its 
3’UTR. Summary of significantly differentially expressed miRNAs upon MYCN induction relative to control treatment (Student t-test, 
Benjamini & Hochberg multiple testing corrected p-value < 0.05). Data are represented in a horizontal bar graph as log 2 fold changes ± 
standard error of the mean (5 biological replicates).
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tumor formation is likely to result from secondary (epi)
genetic events downstream of increased MYCN activity. 
The integration of the screen results with miRNA 
expression data from MYCN non-amplified primary 
neuroblastoma tumors further identified 5 MYCN-
targeting miRNAs with positive correlation to MYCN 
expression or activity. Subsequent analysis of these 
miRNAs in in vivo MYCN model systems showed that 
activation of MYCN is associated to increased expression 
of miR-19a-3p, miR-19b-3p and miR-494-3p. Indeed, 
miR-19a-3p and miR-19b-3p, members of the oncogenic 
miR-17-92 cluster, have been shown to be direct 
transcriptional targets of MYCN in neuroblastoma cells 
[5,24], and the region upstream to miR-494-3p contains 
E-box sequences (data not shown), suggesting that 
MYCN can induce its expression. It is conceivable that 
these miRNAs act both in a MYCN negative regulatory 
feed-back loop as well as via repression of important 
neuroblastoma tumor suppressor genes: indeed, miR-
19a-3p targets ESR1 [32], a ligand-inducible transcription 
factor implicated in neuronal differentiation, whereas 
miR-19b-3p represses DKK3 expression [33], a marker 
of tumor differentiation with elevated expression levels in 
favorable tumors. The MYCN model systems, however, 
cannot confirm the positive correlation between miR-
34c-5p and miR-449a and MYCN expression or activity 
observed in primary neuroblastoma tumors: miR-34c-
5p is consistently downregulated in the murine models, 
whereas the expression of miR-449a is not altered. 
Furthermore, there is no evidence that MYCN could 
induce the expression of these miRNAs directly. Although 
the expression of miR-34c-5p increases upon MYCN 
activation in the in vitro SHEP-MYCN-ER model system, 
the upstream region of miR-34c-5p does not contain E-box 
sequences (data not shown), and miR-449a, residing in the 
second intron of CDC20B, was not identified by Shohet 
and colleagues [24] in their screen for intronic miRNAs 
regulated by MYCN. Nevertheless, the different relation 
between MYCN and miR-34c-5p expression in MYCN 
non-amplified versus amplified environment should not 
be surprising: activation of miR-34c-5p, either direct or 
indirect, could be one of the mechanisms through which 
normal physiological levels of MYCN affect apoptosis. In 
cases where MYCN exceeds its physiological levels and 
oncogene-induced apoptosis is triggered, a transforming 
cell will need to circumvent MYCN-mediated apoptosis, 
for instance via downregulation of miR-34c-5p, which 
seems to occur in TH-MYCN and LSL-MYCN;Dbh-iCre 
tumors.
Of further notice, 17 out of 29 identified MYCN-
targeting miRNAs were considered not to be relevant 
for MYCN regulation in the context of neuroblastoma, 
due to lack of inverse correlation to MYCN expression 
or activity, or due to unavailable expression data. Given 
the tissue specific nature of miRNA function, it is not 
excluded that these miRNAs regulate MYCN in an other 
cellular context, such as that of normal brain development 
[34] and a number of childhood malignancies with 
demonstrated involvement of MYCN: medulloblastoma 
[31,35], retinoblastoma [35,36], Wilms’ tumor [36,37], 
rhabdomyoscaroma [37,38] and T-cell acute lymphoblastic 
leukemia [38]. Notably, three of these excluded 
miRNAs, let-7e-5p, miR-101-3p and miR-202-3p, have 
been reported to target MYCN in a MYCN amplified 
neuroblastoma cell line [3]. This discrepancy between 
literature and our data could be explained by the fact 
that our integrative approach identifies MYCN-targeting 
miRNAs in neuroblastoma using gene expression data 
from MYCN non-amplified primary tumors. Buechner 
and colleagues [3] showed that let-7e-5p, miR-101-3p 
and miR-202-3p are able to affect MYCN expression 
in a MYCN amplified neuroblastoma cell line, whereas 
we found no evidence that they are regulating MYCN in 
MYCN non-amplified primary neuroblastoma tumors.
In conclusion, we identify 12 MYCN-targeting 
miRNAs in with regulatory effects on MYCN expression 
levels or activity in MYCN non-amplified neuroblastoma 
(Fig. 2A). Furthermore, we provide evidence that these 
miRNAs are preferentially downregulated during MYCN-
driven neuroblastoma tumor formation, suggesting 
that MYCN negatively controls the expression of these 
miRNAs, and as such safeguards its own expression. 
Understanding this regulatory miRNAome upstream of 
MYCN in neuroblastoma can open new perspectives for 
targeting the MYCN pathway in neuroblastoma tumors, 
a strategy that holds great promise [39]. Moreover, the 
identification of additional target genes of the miRNAs 
in the described MYCN-miRNA interactome might prove 
useful in the search for novel therapeutic targets.
METHODS
MYCN 3’UTR-miRNA library screen
HEK293T cells were seeded at a density of 10 
000 cells/well in 96-well plates. Twenty-four hours 
after seeding, cells were co-transfected with 100 ng 
of a reporter vector with the wild-type MYCN 3’UTR 
(ENST00000281043, Ensembl release 75) cloned 
downstream of the Firefly luciferase gene (SwitchGear 
Genomics, S207230) and 20 ng of pRL-TK control 
vector containing the Renilla luciferase gene (Promega) 
together with a library of 470 miRNA mimics (2.5 pmol) 
(Ambion’s Pre-miR miRNA Precursor Library - Human 
V3, design based on miRBase v9.2 with exclusion of hsa-
miR-122a). Lipid based transfections were performed 
using 0.4 µl Dharmafect Duo reagent (Dharmacon). 
Forty-eight hours post-transfection, luciferase reporter 
gene activities were assayed using the Dual-Luciferase 
Reporter assay system (Promega) according to the 
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manufacturer’s protocol with minor changes (LARII and 
Stop & Glo buffer volumes were reduced to 50 µl). Firefly 
reporter gene activities were normalized to Renilla values 
and then log-transformed. Subsequently, robust z-scores 
were calculated and median centered to the distribution of 
robust z-scores from 36 analogous screens (of 17 selected 
cancer and disease associated genes) on a per miRNA basis 
in order to remove potential systematic bias. The resulting 
interaction scores are thus more negative for miRNAs 
that interact with the 3’UTR. In order to determine the 
interaction score cutoff that separates interactions from 
non-interactions, the scores for a set of validated miRNA 
interactions, probed in the MYCN screen or any of the 
analogous screens, were used together with the scores 
for a set of negative control interactions from an empty-
3’UTR vector miRNA library screen to perform ROC-
curve analysis and determine the point of highest accuracy 
(interaction score = -1.94, specificity = 99%, sensitivity 
= 51%). MYCN 3’UTR-miRNA library screen results 
were replicated in two independent experiments. For a 
more detailed description of the 3’UTR-miRNA library 
screen setup and data-analysis we refer to Van Peer et al. 
(in preparation).
miRNA target analysis
Potential miRNA target sites in the MYCN 3’UTR 
were identified as reported previously [40]. In addition, 
miRNAs targeting MYCN were predicted using the 
MirTarget2 algorithm [41].
miRNA and mRNA expression in patient cohort
160 MYCN non-amplified primary tumor samples 
of neuroblastoma patients were collected prior to therapy 
at the Ghent University Hospital (Ghent, Belgium), the 
University Children’s Hospital Essen (Essen, Germany), 
the Hospital Clínico Universitario (Valencia, Spain), the 
Academic Medical Center (University of Amsterdam, 
Netherlands) and the National Children’s Research 
Centre (Dublin, Ireland). Informed consent was obtained 
from the patients’ relatives. mRNA data from 75 primary 
neuroblastoma tumors is available at the Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo; Accession 
Number: GSE32664). Correlation of miRNA expression 
levels and MYCN mRNA levels was evaluated with 
Spearman’s rank correlation coefficient. In order to find 
miRNAs that show negative correlation to MYCN activity 
and hence MYCN protein levels, mRNAs were ranked 
according to decreasing Spearman’s rank correlation 
coefficient for each miRNA. Ranked gene lists were used 
for Gene Set Enrichment Analysis (GSEA) [11] with 
selected gene sets of MYC(N) regulated genes from the 
chemical and genetic perturbations gene set collections 
in the GSEA Molecular Signatures Database. From all 
gene sets in this collection that have either MYC or MYCN 
in their name, the six gene sets that contain MYC(N) 
upregulated genes were used for this analysis: COLLER 
MYC TARGETS UP [12], DANG MYC TARGETS UP 
[13], DANG REGULATED BY MYC UP [13], KIM 
MYC AMPLIFICATION TARGETS UP [14], LEE 
LIVER CANCER MYC UP [42], SCHUHMACHER 
MYC TARGETS UP [16] and YU MYC TARGETS UP 
[17]. Gene sets with a false discovery rate (FDR) below 
25% and a normalized enrichment score (NES) below -2 
were considered significantly negatively enriched.
miRNA annotation
In this study we used data obtained with three 
different analytical miRNA platforms. Platform designs 
are based on different releases of the miRBase database 
for miRNA annotation, resulting in non-overlapping 
annotation of data sets. To allow for correct integration 
of miRNA data, we used miRBase Tracker, an in-house 
developed web tool for miRNA reannotation [43] 
and applied the most up-to-date annotation at time of 
publication (miRBase release 21). Details of reannotation 
of the different miRNA platforms, including cross-species 
comparison, can be found in Supplementary Tables S1 - 
S5. 
SHEP-MYCN-ER model system
The MYCN-inducible SHEP-MYCN-ER cell 
model [44] was kindly provided by Johannes H Schulte 
(Department of Pediatric Oncology and Hematology, 
University Children’s Hospital Essen, Germany). Cell line 
authenticity was validated by Short Tandem Repeat (STR) 
genotyping prior to performing the described experiments. 
In the SHEP-MYCN-ER cell line, the cDNA of MYCN is 
fused to a mutated estrogen responsive domain (ER) which 
can bind 4-hydroxy-tamoxifen (4-OHT), but is unable to 
bind with natural estrogen [44]. Addition of 4-OHT to the 
culture medium (200 nM final concentration) activates 
the MYCN-ER expression. SHEP-MYCN-ER cells 
were seeded at 100 000 cells per 6-well and treated with 
4-OHT after 48 h. Subsequently, cells were pelleted for 
RNA isolation 48 h after treatment. In parallel, cells were 
treated with equal amounts of the 4-OHT solvent (70 % 
ethanol) as a negative control. RNA was isolated using 
the miRNeasy Mini Kit (Qiagen; 217004) according to 
manufacturer’s instructions. Five replicate experiments 
were performed and analyzed.
RT-qPCR
RT-qPCR reactions were performed and reported 
according to the MIQE guidelines [45]. For quantification 
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of individual miRNA expressions, cDNA was synthesized 
from 500 ng total RNA with 4 µl of HiSpec Buffer, 2 µl 
of Nucleics Mix and 2 µl miScript RT Mix (miScript II 
RT Kit, Qiagen; 218161) in a final volume of 20 µl. This 
reaction mix was incubated for 60’ at 37°C and 5’ at 95°C 
using an iCycer instrument (Bio-Rad). qPCR reactions 
contained 3 ng of cDNA, 2.5 µl QuantiTeckt Mastermix, 
0.5 µl miScript Universal Primer and 0.5 µl miRNA-
specific miScript Primer Assay (Qiagen, miScript Primer 
Assays used are listed in Supplementary Table S2) in a 
total volume of 5 µl. Expression levels were normalized 
against three stably expressed reference miRNAs (hsa-
miR-125a, hsa-miR-423 and hsa-miR-92) validated with 
GeNorm [46] and analyzed using qbase+ software version 
2.6 (http://www.biogazelle.com/qbaseplus) [47]. 
TH-MYCN neuroblastoma progression model
TH-MYCN+/+ mice [18] were sacrificed at day 
seven (n=4) and day fourteen (n=4) of life to harvest 
sympathetic ganglia containing foci of neuroblast 
hyperplasia, and at week 6 of life to harvest advanced 
neuroblastoma tumors (n=4). Additionally, we have 
dissected the same sympathetic ganglia from TH-
MYCN-/- mice at day seven (n=4), day fourteen (n=4) 
and week 6 (n=4) of life to control for miRNA expression 
changes during normal development. Murine total RNA 
was isolated using the miRNeasy Mini Kit (Qiagen, 
217004) according to the manufacturer’s instructions. 
Mature miRNA expression levels were quantified using 
a stem-loop RT-qPCR platform. Briefly, 99 ng of total 
RNA was reverse transcribed using Megaplex™ RT 
Primers, Rodent Pool Set v3.0 (Life Technologies - 
Applied Biosystems; 4444746) followed by a 12-cycle 
pre-amplification according to the manufacturer’s 
instructions. Pre-amplified cDNA was diluted four 
times and quantified using the TaqMan Array Rodent 
MicroRNA A+B Cards Set v3.0 (Life Technologies 
- Applied Biosystems; 4444909) according to the 
manufacturer’s instructions on a ViiA 7 Real-Time PCR 
System (Life Technologies - Applied Biosystems). Only 
Cq values lower than 32 were retained and normalized 
using global mean normalization, as previously described 
[48]. Furthermore, to allow for cross-species comparison 
of miRNA expression data, we only considered those 
murine miRNA assays that target sequences similar to 
the sequences of the human miRNAs included in our 
3’UTR-miRNA library screen (see Supplementary Tables 
S3 - S4). Linear regression analysis was performed to 
evaluate the differential temporal expression pattern 
in ganglia from wild-type mice and ganglia and tumors 
from transgenic mice. A π-value metric was subsequently 
calculated as the difference in regression slopes 
between transgenic and wild-type samples, multiplied 
with the statistical significance of this difference: 
LSL-MYCN;Dbh-iCre tumors
The LSL-MYCN;Dbh-iCre mouse model is 
described elsewhere [20] along with details on tumor 
dissection and miRNA expression profiling. In brief, 60 
ng of total RNA of normal adrenals and LSL-MYCN;Dbh-
iCre tumors, isolated with the miRNeasy Mini kit 
(Qiagen), was used to quantify murine mature miRNA 
expression levels using a stemloop RT-qPCR platform 
(Life Technologies-Applied Biosystems).
Statistical methods
All statistical analyses were performed using R 
Bioconductor software (version 3.0.2). If not further 
specified in the results section, statistical significance was 
defined as p-value < 0.05 for all statistical tests. 
Data accessibility
mRNA data from 75 primary neuroblastoma tumors 
are available at the Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo) under accession number 
GSE32664. miRNA expression data from the TH-MYCN 
neuroblastoma progression model are available in the 
ArrayExpress database (www.ebi.ac.uk/arrayexpress) 
under accession number E-MTAB-2618. Furthermore, the 
processed data can be visualized via the R2 microarray 
analysis and visualization platform (http://r2.amc.nl) under 
experiment “Exp Nb Hyperplasia TH-MYCN - Ghent - 24 
- custom - mirbase19mm2”.
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